CD10

Laboratory assay overview

To aid in the diagnosis of chronic lymphocytic leukemia or lymphoma. Initial markers evaluated: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD38, CD56, CD64, FMC7, sKappa, sLambda. CD45 is used for gating.

Laboratory assay overview

To aid in the follow-up diagnosis of chronic lymphocytic leukemia or lymphoma. Initial markers evaluated: CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD38, HLA-Dr, sKappa, sLambda. CD45 is used for gating.

Laboratory assay overview

This panel may be used in the initial evaluation of patients with clinical suspicion of hematologic neoplasms. Immunophenotyping by flow cytometry can aid in the diagnosis and classification of leukemia and lymphoma [1]. Subsequent testing of additional cell surface antigens may be needed to help establish a diagnosis. Leukemias and lymphomas are heterogenous morphologically and clinically. Identification of cell surface markers (T cell, B cell, progenitor, and myeloid markers) by flow cytometry can help assign a cell lineage to neoplastic cells. Accurate immunotyping aids in the diagnosis, classification, and prognosis of hematologic neoplasm and may inform treatment decisions [1]. This immunotyping panel is designed to expedite the evaluation of patients without provisional diagnosis of a certain type of hematologic neoplasm. The results of this panel must be interpreted with cytological, histological, genetic, and clinical findings to generate accurate diagnosis. Additional cell surface markers not included in this panel may be needed to evaluate certain hematologic malignancies (eg, hairy cell leukemia). Because non-viable cells lead to non-specific antibody binding, specimens should be processed as early as possible. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. Reference 1. Bain BJ, et al. Leukaemia Diagnosis. 5th ed. John Wiley & Sons;2017:69-134.